Late occurrence of cytomegalovirus (CMV) disease after day 100 after bone marrow transplantation has become an increasing problem; whether a quantitative measurement of CMV DNA in plasma by polymerase chain reaction (P-PCR) could be predictive of such disease was investigated. In a prospective study, 117 subjects undergoing allogeneic marrow transplantation were followed for 120 days with weekly CMV blood cultures, with day 35 bronchoalveolar lavage CMV cultures, with weekly CMV P-PCR, and with clinical follow-up for an additional 1 -2 years. Despite preemptive ganciclovir, CMV disease occurred in 9% of subjects, with a median time of onset of 176 days. Quantitative CMV P-PCR was associated with the late development of CMV disease (P Å .01). Of 43 subjects with positive P-PCR results, 23% developed CMV disease, but no disease occurred in the 74 subjects with negative P-PCR (P õ .001), despite the fact that 22% had CMV isolated from lung lavage fluid and 32% had CMV isolated from blood.
Risk factors for the occurrence of human cytomegalovirus BMT, the presence of CMV DNA in plasma has been associated with risk for disease [3, 4, 12] and pulmonary CMV (CMV) -related morbidity after allogeneic bone marrow transplantation (BMT) can be used to guide antiviral therapy [1 -infection [13] , but the significance of the quantity of CMV DNA in plasma has not been studied. We evaluated whether 5]. The most important of these factors is the occurrence of asymptomatic CMV reactivation in blood or lung [2] , and inquantitative plasma PCR is predictive of late CMV disease. fection of urine or throat has not been as predictive of later disease [1, 2] . In addition, the occurrence of graft-versus-host Methods disease (GVHD), and other factors predisposing to this, such as age ú20 years and HLA mismatch of donor and recipient, Study population. During 1993 -1994 are important risks for CMV infection and disease [6] .
seropositive recipients of allogeneic BMT for hematologic malignancy or severe aplastic anemia were followed for the occurrence With the ability to determine CMV DNA in plasma by polyof CMV infection and disease in a prospective study. CMV infecmerase chain reaction (PCR) [7, 8] , the concentration of viral tion was determined by twice-weekly blood cultures between days DNA can be expressed as genome copies per milliliter and can 28 and 56 (day 0 Å day of marrow infusion) and weekly blood be an indication of CMV virus load. It is not clear whether cultures until day 120, by plasma PCR (P-PCR) for CMV DNA the amount of measurable CMV DNA in blood after BMT on these same blood specimens, and by bronchoalveolar lavage is predictive of disease. In human immunodeficiency virus -(BAL) on day 35 after transplant. After day 120, CMV assays were infected persons, however, it has been reported that the CMV performed only on patients with clinical indications suggestive of DNA concentration is significantly higher in plasma in those possible CMV infection. who eventually develop CMV retinitis [9] and in cerebrospinal Ganciclovir was given preemptively, as previously described fluid in those who develop CMV-related polyradiculopathy [14] , to a total of 71 subjects (62%), based on CMV culture positiv- persons with CMV pulmonary infection [11] . In allogeneic No clinical decision was made on the basis of CMV P-PCR result. Thirty-six patients (31%) were treated because BAL fluid was positive for CMV; among the 81 BAL fluid CMV-negative subjects, an additional 35 were treated with ganciclovir for positive 2 test when adjusting for preemptive ganciclovir treatment. For subjects having a positive Pcurred late after marrow transplant in persons who had already PCR result, Wilcoxon rank sum tests were used to test for a differbeen treated preemptively with ganciclovir. Some early disease ence in median number of genome copies per milliliter of plasma occurred due to failure of culture methods to detect infection, between those with and without CMV disease. The highest number as has been previously described [1, 2] of genome copies (occurring prior to CMV disease, if applicable) CMV load and clinical infection. As shown in figure 1A , positive result in BAL fluid was significantly higher in those with positive than in those with negative P-PCR results (47% Results vs. 22%), which confirms a previous observation [13] . There was no disease in the 74 subjects negative by CMV P-PCR, Occurrence of CMV disease. CMV disease occurred in 10 (23%) of 43 PCR-positive marrow transplant recipients and despite the fact that 22% had detectable CMV in BAL fluid on day 35 after transplant and 32% had positive blood cultures. none of 74 PCR-negative subjects (P õ .001 by Fisher's exact test). There were 3 cases of CMV disease in patients positive
Since it was the trigger for early ganciclovir therapy, progressive CMV infection may have been aborted before it could be for CMV in BAL fluids and 7 in patients with negative BAL fluid results ( JID 1997; 176 (September) and õ10 4 genome copies/mL of plasma had a significantly reduced rate of disease compared with that of subjects with §10 4 genome copies of CMV DNA/mL of plasma (11% vs. 44%; P Å .02 by Fisher's exact test). This result remained the same after adjusting for preemptive ganciclovir treatment by use of the Mantel-Haenszel x 2 test. Interestingly, 21 subjects had a maximum number of genome copies per milliliter before the start of ganciclovir treatment and 19 during treatment. In the 7 subjects with §10 4 genome copies/mL who eventually became ill, all had CMV pneumonitis or gastroenteritis despite preemptive ganciclovir, at a median time of 181.5 days.
When the results were summarized in a contingency table, with the presence of CMV disease used as the reference standard, the sensitivity of any positive CMV P-PCR result was 100%, with specificity of 69%, positive predictive value of 23%, and negative predictive value of 100%. With a cutoff for CMV P-PCR positivity of §10 4 genome copies/mL, the sensitivity of the CMV P-PCR assay was 70%, the specificity 73%, the positive predictive value 44%, and the negative predictive value 89%. As noted above, the occurrence of CMV DNA in plasma was significantly associated with eventual CMV disease. However, the rate of positive culture in BAL fluid or in blood was not significantly associated with CMV disease (P ú .20 for both by Fisher's exact test). The diminished value of these tests for prediction of disease was presumably due to the fact that both tests were used to trigger the start of antiviral therapy, which would decrease disease occurrence.
By use of either a univariate or stepwise logistic regression analysis, the only variable that significantly predicted the probability of developing CMV disease in this group was the number of CMV DNA genome copies per milliliter (P Å .02, by use of a log transformation of the highest number of genome copies) (figure 1B). On the other hand, BAL positivity, blood culture positivity, total amount of preemptive ganciclovir treatment, and occurrence of acute or chronic GVHD were not significantly associated with late CMV disease. The logistic curve does not ascertain the risk of any single subject developing CMV disease when the CMV load is known, but it does illustrate the contribution of increasing CMV burden to the risk of CMV disease occurrence. The ability to measure virus load promises to change the for allogeneic marrow transplant recipients with and without clinway antiviral drug therapy is used. With regard to CMV infecical disease at any time after marrow transplantation. Medians tion after BMT, in which therapy is already based on risk and SEs are shown. There was a significant difference in median assignment, there is the potential for virus load determination value of the highest number of genome copies between patients to further refine this treatment strategy. It has been demonwith and without CMV disease (P Å .01). B, Predicted probability of developing CMV disease, based on stepwise logistic regression strated that increased CMV DNA in the plasma of persons with model using log of genome copies/mL of plasma as predictor of AIDS is associated with a risk for CMV disease of the central CMV disease (P Å .02). 0 on x axis represents 10,000 genome nervous system [9, 10] . Studies are in progress to determine copies/mL, at which point there is 0.2 probability of developing whether early treatment based on risk might be a more precise 
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